Simple Summary In the last 15 years, a deep improvement in the knowledge regarding the
biological mechanisms responsible for neoplastic cell development and progression has led …

Background Several phase 3 studies reported positive results for combinations of Immune-
Oncology (IO) and Vascular Endothelial Growth Factor (VEGF) targeted therapies in patients …

Simple Summary Renal cancer is within the top 10 most common malignancies worldwide,
of which clear cell histology represents the most common subtype in this cancer. Within the …

The therapy of advanced (clear-cell) renal cell carcinoma (RCC) has recently experienced
tremendous changes. Several new treatments have been developed, with PD-1 immune …

Introduction: The combination of immunotherapy and targeted therapy is currently marking a
new era in the treatment of renal cancer. The latest clinical guidelines recommend the use of …

CONTEXT: The expanding armamentarium of agents for the therapy of advanced clear cell
renal cell carcinoma (RCC) warrants further investigation of optimal patient selection …

Majority of patients with clear-cell renal cell carcinoma (ccRCC) at first line (1L) treatment
are classified in the intermediate-risk (IR) subgroup according to International Metastatic …

This clinical case–based discussion focuses on a 73-yr-old man diagnosed with
intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with …

Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most
common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the …

Background Vascular endothelial growth factor (VEGF)-targeted therapy is administered
continuously until progression in metastatic clear cell renal cancer (mRCC). The role of …